NYSE - Nasdaq Real Time Price USD

Medtronic plc (MDT)

Compare
83.23 +0.31 (+0.37%)
As of 10:37:35 AM EST. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
4/30/2024
4/30/2023
4/30/2022
4/30/2021
Total Revenue
32,996,000.00
32,364,000.00
31,227,000.00
31,686,000.00
30,117,000.00
Cost of Revenue
11,533,000.00
11,216,000.00
10,719,000.00
10,145,000.00
10,483,000.00
Gross Profit
21,463,000.00
21,148,000.00
20,508,000.00
21,541,000.00
19,634,000.00
Operating Expense
15,718,000.00
15,628,000.00
14,678,000.00
15,633,000.00
14,739,000.00
Operating Income
5,745,000.00
5,520,000.00
5,830,000.00
5,908,000.00
4,895,000.00
Net Non Operating Interest Income Expense
-766,000.00
-719,000.00
-636,000.00
-553,000.00
-925,000.00
Other Income Expense
178,000.00
37,000.00
170,000.00
163,000.00
-75,000.00
Pretax Income
5,154,000.00
4,837,000.00
5,364,000.00
5,517,000.00
3,895,000.00
Tax Provision
831,000.00
1,133,000.00
1,580,000.00
456,000.00
265,000.00
Net Income Common Stockholders
4,288,000.00
3,676,000.00
3,758,000.00
5,039,000.00
3,606,000.00
Diluted NI Available to Com Stockholders
4,288,000.00
3,676,000.00
3,758,000.00
5,039,000.00
3,606,000.00
Basic EPS
3.28
2.77
2.83
3.75
2.68
Diluted EPS
3.27
2.76
2.82
3.73
2.66
Basic Average Shares
1,306,850.00
1,327,700.00
1,329,800.00
1,342,400.00
1,344,900.00
Diluted Average Shares
1,310,050.00
1,330,200.00
1,332,800.00
1,351,400.00
1,354,000.00
Total Operating Income as Reported
5,409,000.00
5,144,000.00
5,485,000.00
5,752,000.00
4,484,000.00
Total Expenses
27,251,000.00
26,844,000.00
25,397,000.00
25,778,000.00
25,222,000.00
Net Income from Continuing & Discontinued Operation
4,288,000.00
3,676,000.00
3,758,000.00
5,039,000.00
3,606,000.00
Normalized Income
4,568,147.85
3,963,250.00
4,001,225.00
5,181,135.00
3,989,037.23
Interest Expense
766,000.00
719,000.00
636,000.00
553,000.00
925,000.00
Net Interest Income
-766,000.00
-719,000.00
-636,000.00
-553,000.00
-925,000.00
EBIT
5,920,000.00
5,556,000.00
6,000,000.00
6,070,000.00
4,820,000.00
EBITDA
8,560,000.00
8,203,000.00
8,697,000.00
8,777,000.00
7,522,000.00
Reconciled Cost of Revenue
10,558,000.00
10,262,000.00
9,720,000.00
9,171,000.00
9,564,000.00
Reconciled Depreciation
2,640,000.00
2,647,000.00
2,697,000.00
2,707,000.00
2,702,000.00
Net Income from Continuing Operation Net Minority Interest
4,288,000.00
3,676,000.00
3,758,000.00
5,039,000.00
3,606,000.00
Total Unusual Items Excluding Goodwill
-334,000.00
-375,000.00
-345,000.00
-155,000.00
-411,000.00
Total Unusual Items
-334,000.00
-375,000.00
-345,000.00
-155,000.00
-411,000.00
Normalized EBITDA
8,894,000.00
8,578,000.00
9,042,000.00
8,932,000.00
7,933,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-53,852.15
-87,750.00
-101,775.00
-12,865.00
-27,962.77
4/30/2021 - 5/2/1973

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ABT Abbott Laboratories
114.33
+0.17%
 
BSX Boston Scientific Corporation
91.22
+0.73%
 
SYK Stryker Corporation
376.31
+0.04%
 
EW Edwards Lifesciences Corporation
74.51
+0.95%
 
DXCM DexCom, Inc.
80.65
+0.22%
 
ZBH Zimmer Biomet Holdings, Inc.
107.37
+0.43%
 
TMDX TransMedics Group, Inc.
65.98
-2.06%
 
PODD Insulet Corporation
278.61
+1.88%
 
NNOX Nano-X Imaging Ltd.
7.61
+1.11%
 
GMED Globus Medical, Inc.
83.40
+0.55%